Candel Therapeutics, Inc. (CADL) Reports Q2 Loss of $0.74/sh
Tweet
Share
E-mailGet Alerts CADL Hot Sheet
Join SI Premium – FREE
Candel Therapeutics, Inc. (NASDAQ: CADL) reported Q2 EPS of ($0.74), versus ($0.33) reported last year.
For earnings history and earnings-related data on Candel Therapeutics, Inc. (CADL) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Truist Securities Downgrades Covista (CVSA) to Hold
- Citi lowers Ollie's Bargain Outlet price target to $98
- Netskope, Inc. (NTSK) Tops Q2 EPS by 4c, Offers Guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
